Table 2 Baseline characteristics of individual studies included in review
Lead Author, Publication Date (Reference No.) | Location | Year of study | Mean/median age (years) | % male | Indication for index TER | Mean/median interval between stages (months) | Common infecting organism | Common IV ATBs given after revision surgery | Follow up Mean/median (years) | No. of re-infections | No. of deaths | No. of non-infection related adverse events | No. of participants | No. of elbows joints | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
One-stage | |||||||||||||||
 Gille, 2006 [23] | Germany | 1978–1999 | 62.7 | 0.0 | RA (100%) | NA | S. aureus | Flucloxacillin | 6.8 | 1 | 0 | 1 | 5 | 6 | 10 |
 Spormann, 2012 [24] | Switzerland | 1994–2007* | 67.0 | 0.0 | NR | NA | CNSA | Oral ciprofloxacin/rifampin given | 4.0 | 0 | NR | NR | 1 | 1 | 11 |
Two-stage | |||||||||||||||
 Yamaguchi, 1998 [12] | USA | 1981–1994 | 53.8 | 40.0 | RA (80%); OA (20%) | 3.7 | S. aureus; S. epidermidis | None given | 4.1 | 1 | 0 | 1 | 5 | 5 | 11 |
 Yamaguchi, 1999 [22] | USA | 1981–1994 | 59.7 | 28.6 | RA (85.7%); PTA (14.3%) | NR | S. aureus; S. epidermidis | NR | 4.3 | 1 | 0 | 4 | 7 | 7 | 10 |
 Achermann, 2011 [13] | Switzerland | 1994–2007 | NR | NR | RA; OA | 5.5 | NR | Flucloxacillin/rifampin | NR | 0 | NR | NR | 2 | 2 | 9 |
 Spormann, 2012 [24] | Switzerland | 1994–2007 | 54.5 | 100 | RA; PTA; OA; psoriasis | NR | CNSA | Flucloxacillin/rifampin | 6.4 | 0 | NR | NR | 4 | 4 | 11 |
 Peach, 2013 [25] | UK | 1998–2010 | 65.0 | 30.3 | RA; fracture; OA; PTA | 9.0 | CNSA | Cefuroxime | 4.3 | 4 | 0 | 2 | 33 | 34 | 11 |
 Rudge, 2018 [26] | UK | 2009–2014 | 64.7 | 31.6 | RA; PTA; fracture; OA | 6.4 | S. aureus | Tazocin, teicoplanin, amikacin | 3.0 | 3 | 0 | 9 | 19 | 19 | 10 |
 Zmistowski, 2018 [27] | USA | 2001–2016 | NR | NR | PTA; RA; Unknown; fracture | 5.7 | NR | NR | 3.0 | 3 | 0 | 3 | 16 | 16 | 10 |